I know Jeff. But it sounds like Leo feels the same! " The laboratory informed us that additional samples were required for analysis of Kevetrin’s affect on biomarker p21, an early-stage indicator of efficacy.  Those samples have been supplied by the hospital with more to be delivered as the trial progresses.  We are hopeful that data will be available in time for ASCO.”